Evenity is a bone-forming monoclonal antibody designed to inhibit the activity of sclerostin, which allows the drug to rapidly increase bone formation and reduce bone resorption simultaneously.
Screening with bone measurement is recommended for women. Younger women are at more risk.
High levels of serotonin are predictive of an increased risk for hip fracture, nonvertebral osteoporotic fracture, and incident fractures in older men.
Investigators sought to determine whether female reproductive and hormonal factors affect the incidence of total knee arthroplasty for osteoarthritis.
Men with accelerated bone loss have lower estimated bone strength, poorer trabecular microarchitecture, and thinner cortices compared with men without accelerated bone loss.
Negative effects of 2-hour glucose was pronounced at the cortical-bone-dominant sites in women.
Vitamin D levels in preterm infants are significantly correlated with optimal calcium homeostasis and bone mineralization of the femur.
For patients with osteopenia or osteoporosis, taking a bisphosphonate drug holiday is associated with increased risk of fracture for patients with lower femoral neck bone mineral density or T scores.
Investigators sought to determine whether both restrictive and purging types of anorexia nervosa effect bone metabolism.
The 1-year cardiovascular mortality hazard ratio (HR) for alendronate users was 0.33 (95% CI, 0.17 to 0.65) and 0.55 for incident myocardial infarction (95% CI, 0.34 to 0.89).
Anxiety levels are associated with bone mineral density and fracture risk in the lumbar spine and femoral neck among postmenopausal women.
Studies on the antifracture effectiveness of antiosteoporosis medications (or nonpharmacologic treatments) should account for death as a competing risk.
Researchers investigated whether patients with SLE receive lipid testing and statin prescriptions comparably with patients with diabetes.
Findings do not support a role for subclinical thyroid dysfunction as a biomarker for bone-related outcomes in older men.
Researchers showed that improved glycemic control is associated with higher bone resorption, possibly reflecting normalization rather than an abnormal increase in bone resorption.
Researchers sought to determine the predictive value of tibiofemoral MRI, patellofemoral MRI, and KLG1 for the incidence of clinical or radiographic knee OA.
A high stress fracture rate in oligo-amenorrheic athletes, who have whole body, less head and hip, areal bone mineral density (BMD) measures comparable to those of control patients, indicates that BMD in these women may need to be even higher to avoid fractures.
Researchers found that estimation of hip fracture risk without accounting for death as a competing event results in an overestimation of fracture risk.
The USPSTF has released recommendations for vitamin D and calcium supplementation for the primary prevention of fractures in community-dwelling adults.
Crysvita is an antibody that blocks fibroblast growth factor 23 (FGF23), a hormone that causes phosphate urinary excretion and suppresses active vitamin D production by the kidney.
Investigators assessed the association between the cumulative dose of oral glucocorticoid treatment and expense associated with adverse events in patients with rheumatoid arthritis.
Thiazide diuretic use may convey a decreased risk of fracture and as such, the protective effect of this class of medicine should be considered when prescribing thiazide diuretics in clinical practice.
Researchers sought to identify associations of female reproductive factors with incidence of total knee arthroplasty in osteoarthritis.
Anti-osteoporotic medications (mainly bisphosphonates) seem to equally prevent bone loss, especially in the lumbar spine, in patients with diabetes compared with patients without diabetes.
One reason selective serotonin reuptake inhibitors may affect the likelihood of osteoporosis is that the drug antagonizes the serotonin transporter, 5-HTT.
At the 43-month endpoint, a total of 60.7% (307/506) of the abaloparatide followed by alendronate group had ≥3% increase in bone mass at all 3 sites (P<0.0001) vs. 24% (121/505) of the placebo followed by alendronate group.
Intermittent use of high-dose glucocorticoids did not increase the risk for any, osteoporotic, hip, or clinically symptomatic vertebral fractures in patients with chronic obstructive pulmonary disease.
Researchers have determined that treatment for osteoporosis with teriparatide is associated with greater bone formation than treatment with zoledronic acid.
Researchers investigated the effects of growth hormone vs placebo, as well as the effects of sex steroid replacement therapy on bone mineral density in growth hormone-treated young adults with Prader-Willi syndrome who had attained adult height.
In this review, 2 independent investigators searched clinical trial databases for studies that evaluated the link between vitamin D supplements and bone health in adult patients with epilepsy.
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Fatigue Management Contributes to Effective Endometriosis Care
- Assessment of Low-Dose Aspirin As Chemoprevention in Type 2 Diabetes
- Treatment With Alemtuzumab May Frequently Induce Thyroid Dysfunction
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Adjunctive Aripiprazole Lowers Prolactin Levels in Women With Psychosis
- When Physicians Become Patients: Challenges in Seeking Health Care
- Statin Use and Cardiovascular Risk Perception Varies Among Races
- Impact of a Longer Work Week on Diabetes Incidence
- Relationship Between Estradiol Level and Mortality in Elderly Men